These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

391 related items for PubMed ID: 7533221

  • 1. Selective antihypertensive action of moxonidine is mediated mainly by I1-imidazoline receptors in the rostral ventrolateral medulla.
    Haxhiu MA, Dreshaj I, Schäfer SG, Ernsberger P.
    J Cardiovasc Pharmacol; 1994; 24 Suppl 1():S1-8. PubMed ID: 7533221
    [Abstract] [Full Text] [Related]

  • 2. alpha(2)-adrenergic receptors are not required for central anti-hypertensive action of moxonidine in mice.
    Tolentino-Silva FP, Haxhiu MA, Waldbaum S, Dreshaj IA, Ernsberger P.
    Brain Res; 2000 Apr 17; 862(1-2):26-35. PubMed ID: 10799665
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Site-dependent inhibition of neuronal c-jun in the brainstem elicited by imidazoline I1 receptor activation: role in rilmenidine-evoked hypotension.
    Wang X, Li G, Abdel-Rahman AA.
    Eur J Pharmacol; 2005 May 09; 514(2-3):191-9. PubMed ID: 15910806
    [Abstract] [Full Text] [Related]

  • 5. Moxonidine, a centrally acting antihypertensive agent, is a selective ligand for I1-imidazoline sites.
    Ernsberger P, Damon TH, Graff LM, Schäfer SG, Christen MO.
    J Pharmacol Exp Ther; 1993 Jan 09; 264(1):172-82. PubMed ID: 8380858
    [Abstract] [Full Text] [Related]

  • 6. Why imidazoline receptor modulator in the treatment of hypertension?
    Schäfer SG, Kaan EC, Christen MO, Löw-Kröger A, Mest HJ, Molderings GJ.
    Ann N Y Acad Sci; 1995 Jul 12; 763():659-72. PubMed ID: 7677385
    [Abstract] [Full Text] [Related]

  • 7. Analysis of the receptor involved in the central hypotensive effect of rilmenidine and moxonidine.
    Bock C, Niederhoffer N, Szabo B.
    Naunyn Schmiedebergs Arch Pharmacol; 1999 Apr 12; 359(4):262-71. PubMed ID: 10344524
    [Abstract] [Full Text] [Related]

  • 8. Pharmacology of moxonidine, an I1-imidazoline receptor agonist.
    Ziegler D, Haxhiu MA, Kaan EC, Papp JG, Ernsberger P.
    J Cardiovasc Pharmacol; 1996 Apr 12; 27 Suppl 3():S26-37. PubMed ID: 8872297
    [Abstract] [Full Text] [Related]

  • 9. Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent.
    Prichard BN, Owens CW, Graham BR.
    J Hum Hypertens; 1997 Aug 12; 11 Suppl 1():S29-45. PubMed ID: 9321737
    [Abstract] [Full Text] [Related]

  • 10. Low dose of moxonidine within the rostral ventrolateral medulla improves the baroreflex sensitivity control of sympathetic activity in hypertensive rat.
    Wang JL, Wang L, Wu ZT, Yuan WJ, Su DF, Ni X, Yan JJ, Wang WZ.
    Acta Pharmacol Sin; 2009 Dec 12; 30(12):1594-600. PubMed ID: 19960005
    [Abstract] [Full Text] [Related]

  • 11. Responsiveness of α2-adrenoceptor/I1-imidazoline receptor in the rostral ventrolateral medulla to cardiovascular regulation is enhanced in conscious spontaneously hypertensive rat.
    Yamazato M, Nakamoto M, Sakima A, Yamazato Y, Takishita S, Ohya Y.
    Clin Exp Hypertens; 2019 Dec 12; 41(3):255-262. PubMed ID: 29764227
    [Abstract] [Full Text] [Related]

  • 12. Role of medullary I1-imidazoline and alpha 2-adrenergic receptors in the antihypertensive responses evoked by central administration of clonidine analogs in conscious spontaneously hypertensive rats.
    Buccafusco JJ, Lapp CA, Westbrooks KL, Ernsberger P.
    J Pharmacol Exp Ther; 1995 Jun 12; 273(3):1162-71. PubMed ID: 7791087
    [Abstract] [Full Text] [Related]

  • 13. The I1-imidazoline receptor: from binding site to therapeutic target in cardiovascular disease.
    Ernsberger P, Friedman JE, Koletsky RJ.
    J Hypertens Suppl; 1997 Jan 12; 15(1):S9-23. PubMed ID: 9050981
    [Abstract] [Full Text] [Related]

  • 14. Imidazoline receptors associated with noradrenergic terminals in the rostral ventrolateral medulla mediate the hypotensive responses of moxonidine but not clonidine.
    Chan CK, Burke SL, Zhu H, Piletz JE, Head GA.
    Neuroscience; 2005 Jan 12; 132(4):991-1007. PubMed ID: 15857704
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Moxonidine: a new antiadrenergic antihypertensive agent.
    Prichard BN, Graham BR, Owens CW.
    J Hypertens Suppl; 1999 Aug 12; 17(3):S41-54. PubMed ID: 10489098
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Role of I(1)-imidazoline receptors and alpha2-adrenoceptors in hemodynamic effects of moxonidine administration into the rostroventrolateral medulla.
    Khokhlova ON, Murashev AN, Medvedev OS.
    Bull Exp Biol Med; 2001 Apr 12; 131(4):336-9. PubMed ID: 11550020
    [Abstract] [Full Text] [Related]

  • 19. Evidence for the involvement of central I1 imidazoline receptor in ethanol counteraction of clonidine hypotension in spontaneously hypertensive rats.
    El-Mas MM, Abdel-Rahman AA.
    J Cardiovasc Pharmacol; 2001 Sep 12; 38(3):417-26. PubMed ID: 11486246
    [Abstract] [Full Text] [Related]

  • 20. Role of I1-imidazoline receptors within the caudal ventrolateral medulla in cardiovascular responses to clonidine in rats.
    Wang WZ, Yuan WJ, Ren AJ, Pan YX, Tang CS, Su DF.
    J Cardiovasc Pharmacol; 2003 Jul 12; 42(1):1-9. PubMed ID: 12827019
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.